In his latest blog, Russ J Spjut, PharmD, owner of Formulary Intel Consulting, discusses how a newly approved HIV treatment could offer hope for low adherence populations due to its low administration...
The use of second line antiretroviral therapy with ritonavir and lopinavir has increased in recent years, but at this time, little is known about the safety of tenofovir co-administration with LPV/r.
Mylan plans to improve access and increase costs savings within the $20 billion antiretroviral marketplace, by launching 2 of its HIV combination treatments—Symfi Lo and Cimduo—at a significant discount...
Neurological complications are known to be major contributors to morbidity and mortality in patients with HIV. In a recent review, researchers investigated how HIV-associated neurological complications...
The authors of a recent study compared outcomes among patients with HIV and tuberculosis who were treated with daily and intermittent antituberculosis regimens.
Researchers compared the effects of heavy, medium, occasional cannabis use on systemic inflammation and immune activation that is often present in patients with human immunodeficiency virus who are treated...
A recent perspective in the New England Journal of Medicine encouraged more use of generic drugs to treat HIV patients could help states struggling to afford HIV treatments.
